Literature DB >> 1851323

Incidence of hepatitis and seroconversion to hepatitis C virus after open-heart surgery in transfused and non-transfused patients in Sweden.

L Mattsson1, B Aberg, M von Sydow, O Weiland.   

Abstract

The transmission of non-A, non-B hepatitis (NANB)/hepatitis C virus (HCV) was studied in patients undergoing open-heart surgery and related to the reception of blood products and hospitalization and surgery per se. Posttransfusion hepatitis NANB was noticed in 17/390 (4.4%) patients receiving heterologous blood and 8/16 tested became positive for anti-HCV (Ortho HCV ELISA), all within 5 months after onset of hepatitis. Among patients with normal ALAT before surgery and during follow-up, who had received heterologous blood, 1/50 seroconverted after 6 months. This patient probably had a subclinical HCV infection, or possibly a temporary non-specific anti-HCV reactivity with a maximum optical density/cut-off ratio (OD/CO) of 1.2, whereas all posttransfusion hepatitis C cases had OD/CO ratios greater than 4. No hepatitis occurred among the 92 non-transfused patients and no seroconversion was found in any of 62 non-transfused patients tested 6 months after the operation. It was concluded that (1) hospitalization and surgery per se does not seem to offer a risk of hepatitis NANB/C, and (2) seroconversion to for HCV occurs in only 50% of Swedish patients with acute posttransfusion NANB hepatitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851323     DOI: 10.3109/00365549109023370

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN HOSPITALIZED POPULATION SUBSETS.

Authors:  V C Ohri; Mkk Rao; K Banerjee; D Raghunath; K Kher; R M Gupta; S K Nema; Lavan Singh
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Prevalence of antibodies to hepatitis C virus after blood transfusion in heart surgery.

Authors:  R Barcena; A Gonzalez; C Martin-de-Argila; C Ulibarrena; J Graus; L A Grande
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.